News >

Romiplostim Elicits High Responses in Pediatric Immune Thrombocytopenia

Published: Wednesday, Dec 12, 2018

Michael D. Tarantino, MD

Michael D. Tarantino, MD

Most pediatric patients with immune thrombocytopenia (ITP) had rapid and durable platelet responses when treated with the thrombopoietin fusion protein analog romiplostim (Nplate), according to integrated data from 5 clinical trials that were presented at the 2018 ASH Annual Meeting.

Data for 1 patient who had a bone marrow biopsy at investigator request showed an increase in modified Bauermeister bone marrow grade from 0 to 2 without any associated AE. In an ongoing open-label trial, bone marrow biopsies in 32 patients showed no collagen or bone marrow abnormalities.
Tarantino MD, Despotovic J, Roy J, et al. Safety and efficacy of romiplostim in over 200 children with immune thrombocytopenia (ITP): results of an integrated database of 5 clinical trials. In: Proceedings from the 2018 ASH Annual Meeting; December 1-4, 2018; San Diego, California. Abstract 2428.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x